↓ Skip to main content

Safety and effectiveness of apixaban compared to warfarin in dialysis patients

Overview of attention for article published in Research and Practice in Thrombosis and Haemostasis, March 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#50 of 903)
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

twitter
67 X users

Citations

dimensions_citation
79 Dimensions

Readers on

mendeley
83 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety and effectiveness of apixaban compared to warfarin in dialysis patients
Published in
Research and Practice in Thrombosis and Haemostasis, March 2018
DOI 10.1002/rth2.12083
Pubmed ID
Authors

Daniel Reed, Surabhi Palkimas, Rebecca Hockman, Sumner Abraham, Tri Le, Hillary Maitland

Abstract

Background: The use of apixaban for stroke prophylaxis or for the treatment of venous thromboembolism in end stage renal disease (ESRD) patients maintained on dialysis is based on one single-dose pharmacokinetic study. There is a deficiency of clinical evidence supporting safety in this population.Objective: The purpose of this study was to determine the safety and efficacy of apixaban compared with warfarin in dialysis patients.Patients/methods: This is a retrospective cohort study conducted at the University of Virginia Medical Center. A total of 124 ESRD patients maintained on dialysis who either received apixaban (n = 74) or warfarin (n = 50) between January 1, 2014 and October 31, 2016 were included in the study. We used multivariable logistic regression to compare the likelihood of patients experiencing a bleeding event based on anticoagulant therapy.Results: The apixaban group experienced fewer overall bleeding events than the warfarin group (18.9% vs 42.0%; P = .01); this significant difference persisted in adjusted analysis (OR = 0.15; 95% CI = 0.05-0.46; P = .001). Major bleeding events were less frequent in the apixaban group compared with patients on warfarin (5.4% vs 22.0%; P = .01). There were no recurrent ischemic strokes in either groups. A lower, non-significant, incidence of recurrent VTE was found in patients on apixaban compared with warfarin (4.4% vs 28.6%; P = .99).Conclusion: Compared to warfarin, our findings suggest that apixaban is a safe and effective alternative in patients with ESRD maintained on dialysis, with apixaban patients experiencing fewer bleeding events than warfarin patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 67 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 83 100%

Demographic breakdown

Readers by professional status Count As %
Other 10 12%
Student > Bachelor 10 12%
Student > Postgraduate 7 8%
Student > Doctoral Student 7 8%
Researcher 6 7%
Other 17 20%
Unknown 26 31%
Readers by discipline Count As %
Medicine and Dentistry 21 25%
Pharmacology, Toxicology and Pharmaceutical Science 19 23%
Biochemistry, Genetics and Molecular Biology 4 5%
Neuroscience 3 4%
Mathematics 2 2%
Other 6 7%
Unknown 28 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2021.
All research outputs
#990,916
of 25,382,440 outputs
Outputs from Research and Practice in Thrombosis and Haemostasis
#50
of 903 outputs
Outputs of similar age
#22,297
of 345,388 outputs
Outputs of similar age from Research and Practice in Thrombosis and Haemostasis
#3
of 27 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 903 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,388 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.